



SAFETY DATA SHEET

Revision date: 18-Jul-2014

Version: 3.0

Page 1 of 11

1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Fluconazole Powder for Oral Suspension (Greenstone LLC)

Trade Name: Not applicable

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as antifungal agent

Details of the Supplier of the Safety Data Sheet

Greenstone LLC
100 Route 206 North
Peapack, NJ 07977
800-435-7095

Emergency telephone number:
800-435-7095

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Reproductive Toxicity: Category 1B
Effects on or via lactation

US OSHA Specific - Classification

Physical Hazard: Combustible Dust

EU Classification:

EU Indication of danger: Toxic to reproduction, Category 2

EU Risk Phrases:

R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.

Label Elements

Signal Word: Danger

Hazard Statements: H360D - May damage the unborn child
H362 - May cause harm to breast-fed children
May form combustible dust concentrations in air

Precautionary Statements: P201 - Obtain special instructions before use
P202 - Do not handle until all safety precautions have been read and understood
P281 - Use personal protective equipment as required
P260 - Do not breathe dust/fume/gas/mist/vapors/spray
P263 - Avoid contact during pregnancy/while nursing
P264 - Wash hands thoroughly after handling
P270 - Do not eat, drink or smoke when using this product
P308 + P313 - IF exposed or concerned: Get medical attention/advice
P405 - Store locked up
P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
 (Greenstone LLC)
 Revision date: 18-Jul-2014

Page 2 of 11

Version: 3.0

Other Hazards No data available
Australian Hazard Classification (NOHSC): Hazardous Substance. Non-Dangerous Goods.

Note: This document has been prepared in accordance with standards for workplace safety, which require the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warnings included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Citric acid, anhydrous	77-92-9	201-069-1	Not Listed	Not Listed	*
Colloidal silicon dioxide	7631-86-9	231-545-4	Not Listed	Not Listed	*
Fluconazole	86386-73-4	Not Listed	Xn;R22 Repr.Cat.2;R61 R64 R52/53	Acute Tox. 4(H302) Repr. 1B (H360D) Lact. (H362) Aquatic Acute 3 (H402) Aquatic Chronic 3 (H412)	6.6
Sucrose	57-50-1	200-334-9	Not Listed	Not Listed	*
Titanium dioxide	13463-67-7	236-675-5	Not Listed	Not Listed	*

Ingredient	CAS Number	EU EINECS/ELINCS List	EU Classification	GHS Classification	%
Natural orange flavor	NOT ASSIGNED	Not Listed	Not Listed	Not Listed	*
Sodium benzoate	532-32-1	208-534-8	Not Listed	Not Listed	*
Sodium citrate, dihydrate	6132-04-3	Not Listed	Not Listed	Not Listed	*
Xanthan gum	11138-66-2	234-394-2	Not Listed	Not Listed	*

Additional Information: * Proprietary
 Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety.
 In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the R phrases and CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact: Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
(Greenstone LLC)
Revision date: 18-Jul-2014

Page 3 of 11

Version: 3.0

Inhalation: Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure: For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.
Medical Conditions Aggravated by Exposure: None known

Indication of the Immediate Medical Attention and Special Treatment Needed

Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Use carbon dioxide, dry chemical, or water spray.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Carbon monoxide, carbon dioxide, nitrogen oxides and fluorine-containing compounds

Fire / Explosion Hazards: Fine particles (such as dust and mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spilled material by a method that controls dust generation. A damp cloth or a filtered vacuum should be used to clean spills of dry solids. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing dust. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical drug product

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
(Greenstone LLC)
Revision date: 18-Jul-2014

Page 4 of 11

Version: 3.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Colloidal silicon dioxide

Australia TWA	2 mg/m ³
Austria OEL - MAKs	4 mg/m ³
	0.3 mg/m ³
Czech Republic OEL - TWA	0.1 mg/m ³
	4.0 mg/m ³
Estonia OEL - TWA	2 mg/m ³
Finland OEL - TWA	5 mg/m ³
Germany - TRGS 900 - TWAs	4 mg/m ³
Germany (DFG) - MAK	4 mg/m ³
Ireland OEL - TWAs	6 mg/m ³
	2.4 mg/m ³
Latvia OEL - TWA	1 mg/m ³
OSHA - Final PELs - Table Z-3 Mineral D:	20 mppcf
	Listed
Slovakia OEL - TWA	4.0 mg/m ³

Fluconazole

Manufacturer OEL:	500ug/m ³
-------------------	----------------------

Sucrose

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
Australia TWA	10 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Estonia OEL - TWA	10 mg/m ³
France OEL - TWA	10 mg/m ³
Ireland OEL - TWAs	10 mg/m ³
Latvia OEL - TWA	5 mg/m ³
Lithuania OEL - TWA	10 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Slovakia OEL - TWA	6 mg/m ³
Spain OEL - TWA	10 mg/m ³

Titanium dioxide

ACGIH Threshold Limit Value (TWA)	10 mg/m ³
ACGIH OELs - Notice of Intended Changes	Listed
Australia TWA	10 mg/m ³
Austria OEL - MAKs	5 mg/m ³
Belgium OEL - TWA	10 mg/m ³
Bulgaria OEL - TWA	10.0 mg/m ³
Denmark OEL - TWA	6 mg/m ³
Estonia OEL - TWA	5 mg/m ³
France OEL - TWA	10 mg/m ³
Greece OEL - TWA	10 mg/m ³
	5 mg/m ³

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
(Greenstone LLC)
Revision date: 18-Jul-2014

Page 5 of 11

Version: 3.0

Ireland OEL - TWAs	10 mg/m ³ 4 mg/m ³
Latvia OEL - TWA	10 mg/m ³
Lithuania OEL - TWA	5 mg/m ³
OSHA - Final PELs - TWAs:	15 mg/m ³
Poland OEL - TWA	10.0 mg/m ³
Portugal OEL - TWA	10 mg/m ³
Romania OEL - TWA	10 mg/m ³
Spain OEL - TWA	10 mg/m ³
Sweden OEL - TWAs	5 mg/m ³

Exposure Controls

Engineering Controls:

Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.

Personal Protective Equipment:

Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).

Hands:

Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.

Eyes:

Wear safety glasses or goggles if eye contact is possible.

Skin:

Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.

Respiratory protection:

If the applicable Occupational Exposure Limit (OEL) is exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Powder	Color:	White
Odor:	Oranges (natural flavoring added)	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture

Solvent Solubility:	No data available
Water Solubility:	No data available
pH:	No data available.
Melting/Freezing Point (°C):	No data available
Boiling Point (°C):	No data available.
Partition Coefficient: (Method, pH, Endpoint, Value)	

Sodium benzoate

No data available

Sucrose

No data available

Colloidal silicon dioxide

No data available

Xanthan gum

No data available

Sodium citrate, dihydrate

No data available

Natural orange flavor

No data available

Fluconazole

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
(Greenstone LLC)
Revision date: 18-Jul-2014

Page 6 of 11

Version: 3.0

9. PHYSICAL AND CHEMICAL PROPERTIES

Predicted Log P 5.0

Citric acid, anhydrous

No data available

Titanium dioxide

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

Polymerization: Will not occur

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as dust and mists) may fuel fires/explosions.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual ingredients.

Short Term: Active ingredient may be harmful if swallowed. May cause eye irritation (based on components)

Long Term: Repeat-dose studies in animals have shown a potential to cause adverse effects on liver.

Known Clinical Effects: Adverse effects most commonly reported in clinical use include skin rash, headache, nausea, and abdominal pain. Rare cases of serious liver damage and allergic reactions have been reported. There have been reports of multiple congenital abnormalities in infants whose mothers were being treated for 3 or more months with high dose (400-800mg/day) fluconazole. Fluconazole is found in human breast milk at concentrations similar to plasma. Therefore, nursing mothers should limit exposure.

Acute Toxicity: (Species, Route, End Point, Dose)

Sodium benzoate

Rat Oral LD50 4,070 mg/kg

Mouse Oral LD50 1600mg/kg

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
(Greenstone LLC)
Revision date: 18-Jul-2014

Page 7 of 11

Version: 3.0

11. TOXICOLOGICAL INFORMATION

Sucrose

Rat Oral LD50 29.7 g/kg

Xanthan gum

Rat Oral LD50 > 5000 mg/kg

Fluconazole

Rat (F) Oral LD50 1575 mg/kg
Rat (M) Oral LD50 1325mg/kg
Mouse Oral LD50 1410mg/kg
Mouse (M) Oral LD50 1520mg/kg
Dog Intravenous LD50 > 100mg/kg

Citric acid, anhydrous

Rat Oral LD50 3000 mg/kg

Titanium dioxide

Rat Oral LD50 > 7500 mg/kg
Rat Subcutaneous LD50 50 mg/kg

Acute Toxicity Comments:

A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Citric acid, anhydrous

Eye Irritation Rabbit Severe
Skin Irritation Rabbit Mild
No data available

Skin Irritation / Sensitization No data available

Repeated Dose Toxicity: (Duration, Species, Route, Dose, End Point, Target Organ)

Sodium benzoate

10 Day(s) Rat Oral 27370 mg/kg LOAEL Liver, Blood
10 Day(s) Mouse Oral 45 g/kg LOAEL Liver, Kidney, Blood, Ureter, Bladder

Fluconazole

3 Month(s) Rat Oral 5 mg/kg/day NOAEL Liver
6 Month(s) Dog Oral 7.5 mg/kg/day NOAEL Liver
12 Month(s) Rat Oral 10 mg/kg/day LOAEL Liver
12 Month(s) Dog Oral 2.5 mg/kg/day NOAEL Liver

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Sodium benzoate

Embryo / Fetal Development Rat Oral 44 g/kg LOEL Developmental toxicity

Fluconazole

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
(Greenstone LLC)
Revision date: 18-Jul-2014

Page 8 of 11

Version: 3.0

11. TOXICOLOGICAL INFORMATION

Reproductive & Fertility	Rat	Oral 20 mg/kg/day	NOAEL	Negative
Embryo / Fetal Development	Rabbit	Oral 20 mg/kg/day	NOAEL	Maternal Toxicity, Not Teratogenic
Embryo / Fetal Development	Rat	Oral 5 mg/kg/day	NOAEL	Fetotoxicity, Maternal Toxicity
Embryo / Fetal Development	Rat	Oral 80 mg/kg/day	LOAEL	Maternal Toxicity, Developmental toxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Sucrose

Bacterial Mutagenicity (Ames) *Salmonella* Negative

Fluconazole

In Vitro Bacterial Mutagenicity (Ames) *Salmonella*, *E. coli* Negative

In Vivo Cytogenetics Mouse Bone Marrow Negative

In Vitro Cytogenetics Human Lymphocytes Negative

Carcinogenicity: (Duration, Species, Route, Dose, End Point, Effect(s))

Fluconazole

24 Month(s) Rat Female Oral 10 mg/kg/day NOAEL Not carcinogenic

24 Month(s) Rat Female Oral 5 mg/kg/day LOEL Benign tumors, Liver

24 Month(s) Mouse Oral 10 mg/kg/day NOEL Not carcinogenic

Carcinogen Status: See below

Colloidal silicon dioxide

IARC: Group 3 (Not Classifiable)

Titanium dioxide

IARC: Group 2B (Possibly Carcinogenic to Humans)

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this mixture have not been fully evaluated. Harmful effects to aquatic organisms could occur. See Aquatic toxicity data of the active ingredient, below:

Toxicity:

Aquatic Toxicity: (Species, Method, End Point, Duration, Result)

Fluconazole

Daphnia magna (Water Flea) LC50 48 Hours 35 mg/L

Pimephales promelas (Fathead Minnow) LC50 > 50 mg/L

Cyprinodon variegatus (Sheepshead Minnow) LC50 > 50 mg/L

Aquatic Toxicity Comments: A greater than (>) symbol indicates that acute ecotoxicity was not observed at the maximum solubility. Since the substance is insoluble in aqueous solutions above this concentration, an acute ecotoxicity value (i.e. LC/EC50) is not achievable.

Persistence and Degradability: No data available

Bio-accumulative Potential:

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
(Greenstone LLC)
Revision date: 18-Jul-2014

Page 9 of 11

Version: 3.0

Partition Coefficient: (Method, pH, Endpoint, Value)

Fluconazole

Predicted Log P 5.0

Mobility in Soil: No data available

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods:

Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Canada - WHMIS: Classifications

WHMIS hazard class:

Class D, Division 2, Subdivision A



Citric acid, anhydrous

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-069-1

Colloidal silicon dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
------------------------------------	------------

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
 (Greenstone LLC)
 Revision date: 18-Jul-2014

Page 10 of 11

Version: 3.0

15. REGULATORY INFORMATION

California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	231-545-4

Fluconazole

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 3 Schedule 4
EU EINECS/ELINCS List	Not Listed

Natural orange flavor

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
EU EINECS/ELINCS List	Not Listed

Sodium benzoate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	208-534-8

Sodium citrate, dihydrate

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Australia (AICS):	Present
EU EINECS/ELINCS List	Not Listed

Sucrose

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	200-334-9

Titanium dioxide

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	carcinogen initial date 9/2/11 airborne, unbound particles of respirable size
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	236-675-5

Xanthan gum

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present

SAFETY DATA SHEET

Material Name: Fluconazole Powder for Oral Suspension
(Greenstone LLC)
Revision date: 18-Jul-2014

Page 11 of 11

Version: 3.0

15. REGULATORY INFORMATION

EU EINECS/ELINCS List

234-394-2

16. OTHER INFORMATION

Text of R phrases and GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed
Reproductive toxicity-Cat.1B; H360D - May damage the unborn child
Reproductive toxicity, effects on or via lactation; H362 - May cause harm to breast-fed children
Hazardous to the aquatic environment, acute toxicity-Cat.3; H402 - Harmful to aquatic life
Hazardous to the aquatic environment, chronic toxicity-Cat.3; H412 - Harmful to aquatic life with long lasting effects

Xn - Harmful
Toxic to Reproduction: Category 2

R22 - Harmful if swallowed.
R61 - May cause harm to the unborn child.
R64 - May cause harm to breastfed babies.
R52/53 - Harmful to aquatic organisms, may cause long-term adverse effects in the aquatic environment.

Data Sources: The data contained in this MSDS may have been gathered from confidential internal sources, raw material suppliers, or from the published literature.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking. Updated Section 7 - Handling and Storage. Updated Section 11 - Toxicology Information. Updated Section 2 - Hazard Identification. Updated Section 3 - Composition / Information on Ingredients. Updated Section 15 - Regulatory Information. Updated Section 16 - Other Information.

Revision date: 18-Jul-2014
Product Stewardship Hazard Communication

Prepared by: Global Environment, Health, and Safety Operations

It is believed that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time

End of Safety Data Sheet